Carbophenyline as a novel I1 receptor agonist for neuropathic pain relief
Carbophenyline, a potent I1 receptor agonist, offers a new therapeutic approach for neuropathic pain management, potentially providing a safer alternative to current treatments. It shows promise in mitigating chemotherapy-induced neurotoxicity and enhancing pain modulation.
Overview
Carbophenyline is a highly selective imidazoline I1 receptor agonist developed as a novel therapeutic agent for neuropathic pain relief. This innovative compound represents a potential breakthrough in pain management by targeting I1 receptors, which play a significant role in pain modulation. Unlike traditional pain relief medications, carbophenyline offers a safer alternative with its targeted mechanism of action, showing promise in both acute and chronic neuropathic pain scenarios. Additionally, its protective effects against chemotherapy-induced neurotoxicity further highlight its potential clinical applications.
Technical specifications
- Selective Targeting: Carbophenyline is designed to specifically agonize the I1 receptor, which has been implicated in modulating neuropathic pain pathways.
- Dual Action: Demonstrates efficacy in both preventing and alleviating pain symptoms, including allodynia and hyperalgesia, particularly in oxaliplatin-induced models.
- Protective Properties: Offers neuroprotective effects against chemotherapy-induced damage to the central and peripheral nervous systems.
- Pharmacokinetics: Undergoing detailed pharmacokinetic profiling to confirm its solubility, metabolic stability, and permeability.
Technology readiness level
Carbophenyline is currently at a Technology Readiness Level of 4, indicating that it has been validated in laboratory settings with ongoing development to extend its applicability across various neuropathic pain models. Further research and development are focused on synthesizing larger quantities of the compound, analyzing its pharmacokinetics, and evaluating its efficacy and safety in more comprehensive studies.
About University of Camerino
The University of Camerino is a public, multi‑campus research university in central Italy, combining a close‑knit scale with global engagement. Industry collaboration is coordinated by a technology‑transfer and project‑management office that maps expertise, supports proposals and IP, and accelerates spin‑offs. Co‑located assets include a university veterinary teaching hospital in Matelica and earthquake‑resilient research spaces for clinical services, prototyping and testing. Research draws on competitive European and Italian funding, with staff monitoring calls and managing projects; commercialization covers IP, licensing and startups, supported by an annual business‑plan competition.
delivered to your inbox.